Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Ablynx : ABLYNX TO PRESENT AT 2013 J.P. MORGAN HEALTHCARE CONFERENCE



     Ablynx : ABLYNX TO PRESENT AT 2013 J.P. MORGAN HEALTHCARE CONFERENCE

GHENT, Belgium,  7  January 2013  -  Ablynx [Euronext  Brussels:  ABLX]  today 
announces  it  will  present  at  the  31^st  Annual  J.P.  Morgan  Healthcare 
Conference in San  Francisco, California  on Thursday, 10^th  January 2013  at 
12:00 p.m. PST (21:00 p.m. CET).

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and
Chairman of Ablynx. The presentation will  provide an update on the  Company's 
late-stage  proprietary  Nanobody®  programmes,   the  Company's  growth   and 
partnering strategy and the outlook for the near term future.

The presentation will be webcast live and  can be accessed on the day via  the 
Ablynx website at www.ablynx.com. A replay of the webcast will be available on
the Company's website  for 30  days following  the presentation.  To ensure  a 
timely connection, it is recommended that  users register at least 10  minutes 
prior to the scheduled webcast.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on  single-domain 
antibody  fragments,  for  a  range  of  serious  human  diseases,   including 
inflammation, haematology, oncology and pulmonary disease. Today, the  Company 
has approximately  25  programmes  in  the pipeline  and  five  Nanobodies  at 
clinical development  stage. Ablynx  has ongoing  research collaborations  and 
significant  partnerships  with   major  pharmaceutical  companies   including 
Boehringer Ingelheim, Merck  KGaA, Novartis  and Merck  & Co.  The Company  is 
headquartered in Ghent, Belgium.

More information can be found on www.ablynx.com.

For more information, please contact

Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t:   +44 207 920 2330
e:  ablynx@mcomgroup.com

press release in pdf format

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Ablynx via Thomson Reuters ONE
HUG#1668728
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement